Zynex shares surge 14.25% intraday as Chapter 11 filing for strategic restructuring signals path to financial stability.

Zynex Inc. surged 14.25% intraday following its Chapter 11 bankruptcy filing on December 16, 2025, which it framed as a strategic restructuring to secure financial stability and enhance its chronic pain treatment solutions. The company emphasized uninterrupted operations and stakeholder support, including financing from lenders, as part of its plan to strengthen long-term prospects. While bankruptcy typically signals distress, the announcement highlighted continued innovation, patient care focus, and lender confidence, which investors interpreted as a positive step toward operational resilience and market credibility, driving the sharp intraday rally.